Blue test tubes arranged in a line, disappearing into the background

News

NICE ends Skyclarys review

Read time: 1 mins

Published: 21st Mai 2025

NICE (UK): NICE is unable to make a recommendation on omaveloxolone (Skyclarys) for treating Friedreich’s ataxia in people 16 years and over.

NICE (UK): NICE is unable to make a recommendation on omaveloxolone (Skyclarys) for treating Friedreich’s ataxia in people 16 years and over. This is because Biogen withdrew its evidence submission. NICE will review this decision if Biogen decides to make a new submission.

Condition: Friedreichs Ataxia

Type: drug